Reverse Transcriptase Inhibitor

EFdA-TP is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP inhibits HIV-1 RT with multiple mechanisms.

BILR 355 is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI). BILR 355 is highly specific toward HIV-1 reverse transcriptase (RT). BILR 355 can be used for HIV infections research.

Amdoxovir (DAPD) is an orally active nucleoside reverse transcriptase inhibitor. Amdoxovir is active against wild-type and NRTl-resistant viruses. Amdoxovir is the prodrug of dioxolane guanosine. Amdoxovir can be used for research of HIV/AIDS.

Lamivudine-¹⁵N,d₂ is ¹⁵N and deuterated labeled Lamivudine (HY-B0250). Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.

Stavudine-d₄ is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis.

HIV-1-IN-83 (Compound 18E) is a HIV-1 non-nucleoside reverse transcriptase inhibitor with an IC₅₀ of 0.45 μM for wild-type HIV-1 non-nucleoside reverse transcriptase. HIV-1-IN-83 has potent antiviral activity against both HIV-1 wild-type and mutant strains and improves antidrug resistance for Y188L and RES056 mutant strains. HIV-1-IN-83 has no significant toxicity up to 11.088 μM.

GSK5750 is a specific and potent HIV-1 reverse transcriptase ribonuclease H inhibitor with an IC₅₀ value of 0.33 μM. GSK5750 is bound at the RNase H active site through a metalion chelation mechanism.

HIV-1 inhibitor-65 (compound 3c) is an inhibitor of HIV-1 (EC₅₀: 2.9 nM) and an activator of protein kinase C (PKC). HIV-1 inhibitor-65 inhibits syncytium formation (EC₅₀: 7.0 nM) and inhibits HIV-1 entry and HIV-1 reverse transcriptase.

DC20 is an orally active non-nucleoside reverse transcriptase inhibitor with an EC₅₀ of 0.004 μM aganist HIV-1IIIB.

Trovirdine hydrochloride (LY300046 hydrochloride) is a selective non-nucleoside HIV-1 reverse transcriptase inhibitor, with an IC₅₀ value of 0.012 μM against the wild-type enzyme. Trovirdine hydrochloride inhibits the replication of both wild-type and mutant HIV-1, and exerts synergistic or additive effects when combined with some antiviral drugs. Trovirdine hydrochloride is applicable to research related to HIV-1 infection.

Dapivirine-d₄ (TMC120-d₄) is deuterium labeled Dapivirine. Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and nonnucleoside reverse transcriptase inhibitor (NRTI). Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase. Dapivirine (TMC120) regulates autophagy and induced Akt, Bad and SAPK/JNK activations.

HIV-1 inhibitor-53 is a dual HIV-1 protease and reverse transcriptase inhibitor. HIV-1 inhibitor-53 inhibits HIV-1 protease (PR) and reverse transcriptase (RT) activity with IC₅₀ values of 1.93 nM and 2.35 μM, respectively. HIV-1 inhibitor-53 can be used for the research of acquired immune deficiency syndrome (AIDS).

HIV-1 inhibitor-41 (Compound B23) is an orally active non-nucleoside HIV-1 reverse transcriptase inhibitor with EC₅₀ values of 20.8 nM and 50 nM against HIV-1 WT and mutant E138K strain, respectively. HIV-1 inhibitor-41 shows low hERG, no apparent CYP enzymatic inhibition and no acute toxicity.

RDEA 806 is an orally effective non-nucleoside reverse transcriptase (NNRT) inhibitor that exhibits potent in vitro inhibitory activity against wild-type HIV-1 (EC₅₀ = 1.7 ng/mL) and NNRTI-resistant HIV-1. RDEA 806 rapidly reduces HIV-1 RNA viral load in vivo. RDEA 806 has a favorable biosafety profile. RDEA 806 can be used for research related to HIV-1 infection.

Tenofovir (Standard) (GS 1278 (Standard); PMPA (Standard)) is the analytical standard of Tenofovir (HY-13910). This product is intended for research and analytical applications. Tenofovir (GS 1278; PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).

Melanochromone is an HIV-1 reverse transcriptase inhibitor that exhibits anti-HIV-1 activity. Melanochromone can be used in research related to HIV-1 infection.

Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model.

HIV-1 inhibitor-58 (Compound 10c) is a broad-spectrum antiviral agent. HIV-1 inhibitor-58 is a non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-58 inhibits WT strain IIIB, NNRTI-resistant strains (such as K103N and E138K) in MT-4 cells, with EC₅₀ less than 50 nM. HIV-1 inhibitor-58 also inhibits CYP2C9 and CYP2C19 (IC₅₀: 2.06 μM, 1.91 μM). HIV-1 inhibitor-58 can be used for HIV infection reserch.

HIV RT-IN-2 is a HIV reverse transcriptase inhibitor with an IC₅₀ value of 1.2 μM for HIV-1 RT RNA-dependent DNA polymerase. HIV RT-IN-2 potently inhibits all three modes of HIV-1 RT-associated RNase H activity (internal, 3'-DNA directed, 5'-RNA directed cleavage) and inhibits HIV-1 replication. HIV RT-IN-2 can be used for the research of HIV-1 infection.